Avacta Acquires Coris BioConcept to Grow Diagnostics Product Portfolio

Article

Through the acquisition, Avacta gains Coris’ product portfolio consisting of diagnostic tests for respiratory, gastroenteric, and blood-borne pathogens as well as for the detection of antibiotic resistance markers.

Avacta Group announced on June 1, 2023 that it has acquired Coris BioConcept, a Belgium-based provider of rapid diagnostic kits. The acquisition will give Avacta more routes into the diagnostics market, and Avacta will gain appropriate intellectual property-rich product portfolios. This move falls in line with Avacta’s strategy to strengthen its position in the centralized professional healthcare market following its October 2022 acquisition of Launch Diagnostics, a UK-based distributor of in-vitro diagnostics (1).

The transaction includes an upfront cash consideration of £7.4 million (US$9.3 million) and may include an additional earnout cash payment of up to £3.0 million (US$3.6 million) based on future business performance, according to a company press release. Coris recently completed construction of a new 10,700 ft2 facility in Gembloux, Belgium, in March 2023 that houses offices and warehouse space. Coris’ product portfolio consists of diagnostic tests for respiratory, gastroenteric, and blood-borne pathogens, including a COVID-19 lateral flow test, as well as diagnostic kits for the detection of antibiotic resistance markers.

“The acquisition of Coris provides [Avacta] with a broad, professional-use rapid test product portfolio,” said Alastair Smith, CEO of Avacta Group, in the press release. “Complementing the acquisition of Launch Diagnostics last year, the [Coris] acquisition represents an important step in establishing a full-spectrum in-vitro diagnostics business covering centralized, pathology laboratory diagnostics as well as decentralized, point-of-care testing solutions outside the hospital setting.”

Reference

1. Avacta Group, Proposed Acquisition of Launch Diagnostics. Press Release, Oct. 18, 2022.

Source: Avacta Group

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Lee Cronin, founder and CEO of Chemify
Nicole Hunter, head of Global WMArchitect at Watson-Marlow Fluid Technology Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.